UNSPSC 51281603: Apramycin

This classification denotes an antibiotic with the molecular formula C21H41N5O11, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 388K3TR36Z, chemically known as 4-o-((8r)-2-amino-8-o-(4-amino-4-deoxy-alpha-d-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-d-glycero-alpha-d-allo-octodialdo-1,5:8,4-dipyranos-1-yl)-2-deoxy-d-streptamine but generally known as apramycin, which bears US NIH Compound Identifier 71428. Apramycin most often comes in base and sulphate forms.

UNSPSC 51281603 Apramycin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two opportunities posted under this code in the source window do not represent purchases of apramycin or related aminoglycoside antibiotics; instead, they reflect a mismatch between the code assigned and the actual work solicited. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets — neither of which is apramycin. Seminole County, Florida posted an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems, which also falls outside the apramycin commodity scope. These mislabelings suggest either coding errors in the state and local procurement systems tagging these opportunities or a divergence between the code's intended scope and current purchasing practice.

Given the absence of substantive recent apramycin solicitations, the code presents limited market signals for business development. The issuing bodies appearing in the record — a state health department and a county government — are typical customers for pharmaceutical and medical supplies, but the actual commodities they are procuring do not align with apramycin or its therapeutic class. No geographic concentration is evident, and no representative apramycin-specific opportunities appear in the recent record. Firms evaluating this code should treat current activity as dormant unless independent market research uncovers apramycin demand from state animal-health programs, agricultural extension services, or veterinary procurement offices not reflected in this source.